Acrivon's WEE1/PKMYT1 Inhibitor Shows Durable Responses in Lung Cancer, Advances to Randomized Dose Expansion
ACRV sits 31% above its 52-week low of $1.2.
Summary
ACR-2316, a potential first-in-class dual WEE1/PKMYT1 inhibitor, is moving into randomized dose expansion after showing durable single-agent activity in heavily pretreated patients. In lung cancer, the disease control rate hit 86% (2 PRs, 4 SD) with some patients on treatment over a year. The safety profile looks clean—no grade ≥4 TRAEs, and grade 3 events were limited to transient neutropenia. Doses of 120 mg and 160 mg on a 3-day-on/4-day-off schedule will be tested in biomarker-selected populations including SCLC, NSCLC, endometrial, cervical, and esophago-gastric cancers. This is the first clinical validation of the AP3 platform's ability to design drugs that overcome resistance to single-target inhibitors. With a $67M market cap, positive early data in a high-unmet-need space could significantly de-risk the pipeline and attract partnership interest.
At the time of this announcement, ACRV was trading at $1.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $66.8M. The 52-week trading range was $1.20 to $3.56. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.